You are here: Industry Insights > cancer treatments

News List

Growing role of personalised and precision medicine in cancer treatments europeanpharmaceuticalreview
January 30, 2019
The role of personalised and precision medicine may be ideal for the treatment of cancer, but questions about consequences and society issues still remain…
Sanofi revises immuno-oncology deal with Regeneron pharmaceutical-technology
January 08, 2019
Sanofi and Regeneron Pharmaceuticals have revised a global immuno-oncology discovery and development agreement to develop new treatments for cancer......
Three cancer treatments approved for use on NHS Scotland pharmatimes
July 16, 2018
Three treatments have been approved for NHS funding in Scotland, bringing new options for gastroenteropancreatic tumours, lung and kidney cancers, but patients with multiple sclerosis will be unable to access Roche’s Ocrevus following a rejection by the S
Novartis’ Rydapt receives approval for two cancer treatments in the EU pharmaceufical-technology
September 25, 2017
The European Commission (EC) has approved Novartis’ Rydapt (midostaurin) for two indications in rare, hard-to-treat cancers.
3 in 4 of CDF treatments now approved on NHS pharmaceutical-technology
August 16, 2017
75% of cancer treatments previously accessible through the Cancer Drugs Fund (CDF) are now available for patients on the NHS England.
Fusion Pharmaceuticals Launches to Develop Targeted Radiotherapeutics as Cancer Treatments americanpharmaceuticalreview
February 27, 2017
Fusion Pharmaceuticals, a newly formed biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the closing of a $25 million Series A financing led by founding venture investor,